Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (8 quarters reported)
$175M in Q4 2020 → $73.2M now. Hover for any quarter.
As reported for the quarter ended September 30, 2022. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Rapt Therapeutics Inc | 52.5% | Unchanged | 1,599,417 | $38.5M |
| Ngm Biopharmaceuticals Inc | 23.2% | Unchanged | 1,298,908 | $17M |
| Revolution Medicines Inc | 18.4% | Unchanged | 685,011 | $13.5M |
| Nurix Therapeutics Inc | 5.8% | Unchanged | 327,123 | $4.26M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.
quarter ended September 30, 2022 · filed November 14, 2022
No position changes this quarter.
quarter ended June 30, 2022 · filed August 15, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nurix Therapeutics Inc | Added | +1 | +$13 | 6.5% |
quarter ended March 31, 2022 · filed May 16, 2022
No position changes this quarter.
quarter ended December 31, 2021 · filed February 11, 2022
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nurix Therapeutics Inc | Trimmed | −234,451 | −$6.79M | 8.7% |
quarter ended September 30, 2021 · filed November 12, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| CP Constellation Pharmaceuticals Inc. | Exited | −1,880,623 | −$63.6M | — |
| Nurix Therapeutics Inc | Trimmed | −124,701 | −$3.74M | 14.9% |
quarter ended June 30, 2021 · filed August 16, 2021
No position changes this quarter.
quarter ended March 31, 2021 · filed May 17, 2021
No position changes this quarter.
Loading...
